GNA Biosolutions Reveals New Ultrafast PCR Platform

By PR Newswire | 11.12.17

The Pharos V8 is the company's first platform to come on the market.

GNA Biosolutions GmbH, a molecular technology company based in Martinsried, Germany, recently announced the launch of Pharos V8, the world's first Laser PCR platform. Pharos V8, an ultrafast PCR instrument for in-vitro research use, is being showcased at the Medica Trade Fair (Exhibition Hall 3, Booth E93) in Düsseldorf, Germany, from November 13-16.
The patented technology behind the Pharos V8 platform is Laser PCR. Laser PCR operates on the same principles as conventional nucleic acid amplification with PCR (Polymerase Chain Reaction). However, Laser PCR uses nanomaterials to control temperature cycles at the nano scale, accelerating PCR reaction times by a factor of ten and opening the door for applications in multiple time-sensitive settings.
The Pharos V8 is the company's first platform to come on the market, with additional product launches planned over the next two years. Key features of the Pharos V8 include:
  • An open platform for universal PCR assay development
  • Ultrafast real-time nucleic acid detection in 10 minutes or less
  • Intuitive interface with easy-to-use software that can be accessed remotely
Frank Krieg-Schneider, CEO of GNA Biosolutions stated, "We are excited to present our first Laser PCR platform, the Pharos V8, at this year's Medica. We believe the Pharos V8 will demonstrate the power of our patented technology to deliver ultrafast molecular results, and pave the way for additional platforms in development for diagnostic testing and point of care."